Working… Menu

Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00763971
Recruitment Status : Completed
First Posted : October 1, 2008
Results First Posted : March 22, 2012
Last Update Posted : June 14, 2021
Information provided by (Responsible Party):
Takeda ( Shire )

Brief Summary:
The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.

Condition or disease Intervention/treatment Phase
ADHD Drug: Lisdexamfetamine Dimesylate (LDX) Drug: Methylphenidate Hydrochloride Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 336 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Actual Study Start Date : November 17, 2008
Actual Primary Completion Date : March 16, 2011
Actual Study Completion Date : March 16, 2011

Arm Intervention/treatment
Experimental: Lisdexamfetamine Dimesylate (LDX)
Overencapsulated LDX 30, 50, or 70mg
Drug: Lisdexamfetamine Dimesylate (LDX)
30, 50 or 70mg capsule once per day (Overencapsulated)
Other Name: Vyvanse™

Active Comparator: Methylphenidate Hydrochloride
Overencapsulated Concerta 18, 36, or 54mg
Drug: Methylphenidate Hydrochloride
18, 36, or 54mg tablet one per day (Overencapsulated)
Other Name: Concerta®, OROS MPH

Placebo Comparator: Placebo
Overencapsulated Placebo
Drug: Placebo
Placebo capsule once per day (Overencapsulated)

Primary Outcome Measures :
  1. Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks [ Time Frame: Baseline and up to 7 weeks ]
    The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.

Secondary Outcome Measures :
  1. Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores [ Time Frame: Up to 7 weeks ]
    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

  2. Change From Baseline in Conner's Parent Rating Scale - Revised (CPRS-R) Total Score at up to 7 Weeks [ Time Frame: Baseline and up to 7 weeks ]
    The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior.

  3. Health Utilities Index-2 (HUI-2) Scores at up to 7 Weeks [ Time Frame: Baseline and up to 7 weeks ]
    HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.

  4. Change From Baseline in the Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at up to 7 Weeks [ Time Frame: Baseline and up to 7 weeks ]
    The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.

  5. Change From Baseline in Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at up to 7 Weeks [ Time Frame: Baseline and up to 7 weeks ]
    The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.

  6. Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at up to 7 Weeks [ Time Frame: Baseline and up to 7 weeks ]
    The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.

  7. Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Up to 7 weeks ]
    C-SSRS is a 19-item semi-structured interview designed to capture suicide-related thoughts and behaviors.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject is a male or female aged 6-17 years inclusive at the time of consent.
  2. Subject must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation.
  3. Subject must have a Baseline ADHD-RS-IV total score ≥28.
  4. Subject has blood pressure measurements within the 95th percentile for age, gender, and height at Screening and Baseline.
  5. Subject is able to swallow a capsule.

Exclusion Criteria:

  1. Subject has failed to respond to more than one adequate course (dose and duration) of stimulant therapy. One course must have been a long-acting formulation.
  2. Subject has a conduct disorder. Oppositional Defiant Disorder is not exclusionary.
  3. Subject is currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently, demonstrating active suicidal ideation.
  4. Subject has glaucoma.
  5. Subject weighs less than 22.7kg (50lbs).
  6. Subject is significantly overweight based on Centre for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts at Screening. Significantly overweight is defined as a BMI >97th percentile for this study.
  7. Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or methylphenidate.
  8. Subject has a documented allergy, hypersensitivity, or intolerance to any excipients in the test or reference products.
  9. Subject has a history of seizures (other than infantile febrile seizures), a tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
  10. Subject has a known history of symptomatic cardiovascular disease, advance arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
  11. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  12. Subject is well controlled on their current ADHD medication with acceptable tolerability.
  13. Subject has a pre-existing severe gastrointestinal tract narrowing (pathologic or iatrogenic).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00763971

Show Show 49 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: Study Director Takeda
Additional Information:
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Shire Identifier: NCT00763971    
Other Study ID Numbers: SPD489-325
2008-000679-90 ( EudraCT Number )
First Posted: October 1, 2008    Key Record Dates
Results First Posted: March 22, 2012
Last Update Posted: June 14, 2021
Last Verified: June 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Lisdexamfetamine Dimesylate
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents